Value is subjective. Nevertheless, most Fools would agree that it can be a good idea to buy shares trading on price weakness so long as a companyslong-term prospects havent changed. Given this, lets cialis online look atthree companies in the markets top tier that look like decent picks today.
Priced to go?
After rising sharply to a peak of 5,220p following Junesreferendum result, shares in FTSE 100 pharmaceutical giant, Astrazeneca (LSE: AZN) have now fallen 22% over the last few months. This follows a disappointing set of Q3 results and ongoing concerns about its ability togenerate sufficient numbers ofnew treatments to battle itspatent cliff. Not even Hilary Clintons failure to capture the White House andimplementprice restrictions on the drug industry has beenenough to stop some investors heading for the exits.
Notwithstanding these issues, shares in Astrazencea look fairly cheap right now on a price-to-earnings (P/E) ratio of just 12. Aslong as thingsdoimprove (earnings per share are expected to grow by 20% and 23% over the next two years), theres also a relatively safe yield of 5.4% on offer. Thats an awful lot more than youll get from any savings account.
Ad appeal
This one dippedalmost 3% yesterday on news that the US i take viagra Justice Department is investigating claims that advertising companies are involved in rigging the bidding process for contracts on commercials by promoting their ownin-house production units. But I still think thatWPP (LSE: WPP) remains a decent choicefor those craving hassle-free stocksfor their portfolios. Lets not forget that this is a company that managed to more than double earning per share between 2010 and 2015.
With a forecast P/E of 13, a fully-covered 3.7% yield pencilled-in for next year and Martin Sorrell at the helm, now could be a great opportunity to grab a slice of theresilient FTSE 100 constituent.
Finally, theres Sky (LSE: SKY). Like Astrazeneca, its shares have been on a downward trajectory over the last year, falling 27%to todays price of 786p. Nevertheless, withdetails of new product launches, a 7% increase in sales (compared buy cialis online to Q1 in 2015) and 100,000 new customers, Octobers positive Q1results suggest this fall may be overdone.
With a P/E of just over 13, Id say that shares in Sky are fairly priced, despite the increased competition it faces from companies like BT. A forecast yield of just under 4.5% for 2017 also looks safe aslong as the company cancontinue to build on the aforementioned figures.
Knowthyself
Ultimately, no one knows cheap viagra online what the future will bring. Just ask investors in quality spread betting firms like IG Index and CMC Markets how their week is going.
Although Astrazeneca, WPP and Sky all look temptingat the current time, this isnt to say that their shares prices couldnt sink lower given the unpredictable nature of the markets. This is why its so important for each and every Foolish investor to consider their tolerance to risk, financial goals and investing horizon before buying a slice of any company.
Thankfully, the multinational nature of all of the above means that theyre not dependent on any one market. This viagranoprescription-buy is particularly important given the uncertain political and economic climate weve endured in 2016 and given next years French and German elections that looks likely to continue well into 2017.
Buying shares on temporary price weakness is just one way of increasing your chances of walking away from the stock market with a cool million in your back pocket.
If you’re looking for a long and profitable investing career (and who isn’t?), I strongly encourage you to follow the 10 steps recommended by the experts at the Motley Fool. They’re all here in a completely FREE special report.
Paul Summers has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Sky. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.